FDA Requires GLP-1 Drugmakers to Add Vision-Loss Warning to All Labels
The agency mandated a warning about NAION, a rare optic nerve condition that can cause sudden, permanent blindness, on every approved GLP-1 medication, including Ozempic, Wegovy, Zepbound, and Mounjaro.
The Food and Drug Administration told manufacturers of GLP-1 receptor agonist drugs on November 9 that they must add language to their labels warning patients of a potential increased risk of non-arteritic anterior ischemic optic neuropathy, a condition clinicians abbreviate as NAION. The requirement covers every currently marketed drug in the class.
According to a drug safety communication reviewed by CNN, the named drugs include Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy. A Lilly spokesperson told CNN the company was "carefully evaluating the update" and would respond to the FDA promptly.
NAION is not a condition most patients have heard of, and the name doesn't make it easier to explain at the bedside. It happens when blood flow to the optic nerve drops sharply, damaging the fibers that carry visual signals from the eye to the brain. As NBC News reported, the condition can cause sudden, painless vision loss in one eye and, in some cases, permanent impairment. The FDA confirmed in its communication that there is no known treatment.
The agency based its decision on data from more than 125 randomized, controlled clinical trials of GLP-1 drugs, according to reporting by Fortune. That review translated into roughly 2.6 extra NAION cases per 100,000 patients on these medications, a low absolute number that the FDA nonetheless judged meaningful enough to require disclosure. The agency noted in its safety communication that NAION cases have been reported for every GLP-1 drug currently on the market, not just the high-profile semaglutide and tirzepatide brands.
What the agency still doesn't know is why. As reported by CBS News and cited in coverage by draxe.com, the FDA said the biological mechanism linking GLP-1 drugs to NAION is not understood. That's a clinically important gap. Without a mechanism, there's no way to identify which patients face the highest exposure, or whether the risk is tied to dose, duration, the drug's glucose-lowering effect, or something else entirely.
Manjot Gill, an ophthalmologist at Northwestern Medicine, told NBC News that the FDA's decision to require a label warning was appropriate. Speaking separately to the Washington Post, Gill said patients who are taking or considering GLP-1 drugs shouldn't be immediately discouraged, a view that tracks with the raw numbers. At 2.6 excess cases per 100,000, the absolute risk remains low for any individual patient. But patients who notice sudden blurred vision, blind spots, or color distortion in one eye while on these medications now have a labeled reason to call their eye doctor the same day, not wait for the next routine visit.
The timing is worth noting. The FDA moved to strip a suicide-risk warning from GLP-1 labels in January after a full safety review found no signal. This new NAION warning moves in the other direction, adding a risk disclosure where the evidence was strong enough to act even without a confirmed mechanism. That's a narrower evidentiary bar than a confirmed causal link, and clinicians prescribing these drugs to the tens of millions of Americans now on them will want to document that the conversation happened.
Opthalmologists will likely see the downstream effect before endocrinologists or primary care physicians do. Patients who experience NAION often present to eye clinics with no warning and no prior symptoms. With a label change now in place, those encounters should start including a medication history that explicitly asks about GLP-1 use.
Sources cited:
- CNN (https://www.cnn.com/2026/11/09/health/glp1-vision-loss-fda-warning)
- NBC News (https://www.nbcnews.com/health/health-care/fda-orders-new-warning-glp-1s-rare-eye-condition-linked-sudden-blindne-rcna608309)
- Washington Post (https://www.washingtonpost.com/health/2026/11/10/fda-has-new-warning-about-glp-1s-vision-loss-should-you-worry/)
- Fortune (https://fortune.com/2026/11/13/glp-1-drugs-fda-warning-eye-stroke-naion-vision-loss/)
This release was originally distributed via ETL Newswire. Visit CNN for the full story, related releases, and contact information.
Visit CNN →